Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Chimeric antigen receptor (CAR) engineered natural killer (NK) cells show great promise against hematological malignancies in recent advances. Multiple methods for genetic engineering of PBMC-derived NK cells and continuously expanding NK cells are well established during the past decade, which facilitates the generation and expansion of novel NK cells with optimized therapeutic efficacy. To enhance the therapeutic utility of CAR-NK cells, Creative Biolabs provides a variety of genetic strategies for engineering next-generation NK cells.
To overcome some of the limitations of NK cell therapy, we have adopted a variety of genetic engineering strategies to address the above mentioned limitations. Specifically, these strategies include activation of exogenous receptor expression or selective down-regulation of inhibitory receptors to improve CAR-NK cytotoxicity; down-regulation of inhibitory cytokines and introduction of dominant negative receptors to reduce tumor environmental sensitivity; expression of chemokine receptors to increase in vivo proliferation and persistence through autocrine cytokine stimulation and tumor homing.
More specifically, we currently provide the following genetic engineering services for CAR-NK cells:
For more customized NK-based genetic engineering services, don't hesitate to leave us a message!
NK Cell Genetic Engineering can be conducted by our CRISPR-edited CAR Cell Technology platform. This powerful platform combines CAR cell therapy with CRISPR technology, which unleashes the therapeutic potential of CAR cell therapy and enables our global customers to push their projects into clinical trials. Our CRISPR/Cas9 system has been used to knock out and knock into multiple CAR cell genome editing sequences, such as CAR-T, CAR-NK, and CAR-MA cells, as well as CAR-stem cells.
Notably, as the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NK therapy development, including but not limited to:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
